Golimumab associated with risk of serious fungal infections
Centocor Ortho Biotech has issued a Dear Healthcare Professionals letter to remind healthcare providers that golimumab (Simponi), a tumor necrosis factor (TNF)-alpha blocker, is associated with a risk of serious fungal infections.
Centocor Ortho Biotech has issued a Dear Healthcare Professionals letter to remind healthcare providers that golimumab (Simponi), a tumor necrosis factor (TNF)-alpha blocker, is associated with a risk of serious fungal infections. FDA has stated that histoplasmosis and other invasive fungal infections are not consistently recognized in patients being treated with other TNF-alpha blockers, including certolizumab pegol (Cimzia, UCB), etanercept (Enbrel, Amgen/Wyeth), adalimumab (Humira, Abbott), and infliximab (Remicade, Centocor Ortho Biotech). This lack of recognition has led to delays in treatment, sometimes resulting in death.
Golimumab was recently approved for the treatment of moderate-to-severe rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), and ankylosing spondylitis.
Healthcare professionals should carefully weigh the potential risks and benefits of treatment in individual patients before initiating golimumab therapy.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
